Insmed Acquires Gene Therapy Company
Ticker: INSM · Form: 8-K · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: acquisition, rare-disease, gene-therapy
TL;DR
Insmed just bought a gene therapy company to boost its rare disease pipeline.
AI Summary
Insmed Incorporated announced on August 8, 2024, that it has completed the acquisition of a gene therapy company for an undisclosed amount. This strategic move aims to expand Insmed's pipeline in rare diseases. The filing does not provide specific financial details of the acquisition but signals a significant step in the company's growth strategy.
Why It Matters
This acquisition could significantly bolster Insmed's presence in the rare disease market by adding new gene therapy assets to its pipeline.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, valuation, and the success of the acquired assets, especially in the complex gene therapy field.
Key Players & Entities
- Insmed Incorporated (company) — Registrant
- Virginia (jurisdiction) — State of incorporation
- 000-30739 (company_id) — Commission File Number
- 54-1972729 (company_id) — IRS Employer Identification No.
- 700 US Highway 202/206 Bridgewater, New Jersey 08807 (address) — Principal executive offices
- August 8, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K filing is to report a material event, specifically the completion of an acquisition by Insmed Incorporated.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 8, 2024.
What is Insmed Incorporated's state of incorporation?
Insmed Incorporated is incorporated in Virginia.
What is the principal executive office address for Insmed Incorporated?
The principal executive office address is 700 US Highway 202/206 Bridgewater, New Jersey 08807.
What is the Commission File Number for Insmed Incorporated?
The Commission File Number for Insmed Incorporated is 000-30739.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-08 07:00:26
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select
Filing Documents
- ef20033779_8k.htm (8-K) — 27KB
- ef20033779_ex99-1.htm (EX-99.1) — 250KB
- image00001.jpg (GRAPHIC) — 2KB
- 0001140361-24-036279.txt ( ) — 439KB
- insm-20240808.xsd (EX-101.SCH) — 4KB
- insm-20240808_lab.xml (EX-101.LAB) — 21KB
- insm-20240808_pre.xml (EX-101.PRE) — 16KB
- ef20033779_8k_htm.xml (XML) — 4KB
02 – Results of Operations and Financial Condition
ITEM 2.02 – Results of Operations and Financial Condition. On August 8, 2024, Insmed Incorporated (the "Company") issued a press release regarding its financial results for the three months and six months ended June 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The information contained herein, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 – Financial Statements and Exhibits
ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on August 8, 2024. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 8, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary